Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Company Overview

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $8.05 to $8.62
• 50-Day Range: $4.80 to $10.01
• 52-Week Range: $2.91 to $12.40
• Volume: 736,090 shs
• Average Volume: 760,506 shs
• Market Capitalization: $513.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Monte Rosa Therapeutics Stock Analysis - MarketRank™

Monte Rosa Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 435th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Monte Rosa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Monte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monte Rosa Therapeutics is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monte Rosa Therapeutics is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monte Rosa Therapeutics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.00% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 49.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monte Rosa Therapeutics does not currently pay a dividend.

Dividend Growth

Monte Rosa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.00% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 49.90%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Monte Rosa Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 1 article on an average week.

Search Interest

17 people have searched for GLUE on MarketBeat in the last 30 days.

MarketBeat Follows

7 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,573,438.00 in company stock.

Percentage Held by Insiders

Only 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.

Percentage Held by Institutions

79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLUE Stock Analysis - Frequently Asked Questions

How have GLUE shares performed this year?

Monte Rosa Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, GLUE shares have increased by 48.0% and is now trading at $8.36.
View the best growth stocks for 2024 here.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.16. The company earned $9.22 million during the quarter, compared to analysts' expectations of $4.54 million.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Who are Monte Rosa Therapeutics' major shareholders?

Monte Rosa Therapeutics' top institutional shareholders include FMR LLC (8.30%), Geode Capital Management LLC (1.70%), Vestal Point Capital LP (1.51%) and State Street Corp (1.12%). Insiders that own company stock include Versant Venture Capital Vi, L and Edmund Dunn.
View institutional ownership trends.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Monte Rosa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLUE
• CUSIP: N/A
• CIK: 1826457
• Web: www.monterosatx.com
• Phone: 617-949-2643
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +91.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-135,350,000.00
• Net Margins: N/A
• Pretax Margin: -794.69%
• Return on Equity: -62.68%
• Return on Assets: -38.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.03
• Quick Ratio: 6.03

Sales & Book Value

• Annual Sales: $14.98 million
• Price / Sales: 34.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.58 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 61,437,000
• Free Float: 57,444,000
• Market Cap: $513.61 million
• Optionable: Optionable
• Beta: 1.30